Amgen Q2 sales rise, company to lay off up to 2,900

Share this article:
Amgen's Prolia, Enbrel get sales overhauls, DTC
Prolia sales soared 40%, to $264 million, compared to the same period last year

Amgen powered through its second quarter with sales rising to $4.9 billion, up 8% compared to the same period last year, when sales hit $4.6 billion.

Much of the bounce came from RA drug Enbrel, which saw sales grow 7% to $1.2 billion, compared to the same period last year, due largely to price. Cancer drug Krypolis brought in $78 million in sales, but has no comparative performance, having joined Amgen's portfolio in the late-2013 Onyx acquisition.

Bone drug denosumab, when labeled Prolia, had sales soar 40% to $264 million, compared to the same period last year, due to increased demand. When labeled Xgeva, denosumab sales grew 20% to $299 million, compared to the same period last year. Amgen notes that higher demand drove Xgeva sales “despite competition from generic zoledronic acid.”

Sales of biologics Neupogen and Neulasta dipped 9% to $1.4 billion, compared to the same period last year. Medicaid rebates from 2013 played into some of this comparative decline, as so did sales for its competition. Generic competition will almost certainly increase now that Sandoz has filed its Neupogen biosimilar with the FDA.

The financials also came with a side of pink slips—Amgen announced it was laying off between 2,400 and 2,900 employees beginning this year and running into 2015. This first stage of the reorganization includes shuttering sites in Washington and Colorado. Amgen expects the cuts will trigger $700 million in savings by 2016. The firm said it expects to reinvest this money in the business.

Amgen expects to provide more reorganization details later this year.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...